Findings

What do systematic reviews say?

41 questions · 41 findings · 4 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 20 · 48.8%GRADE not reported 0 · 0%Very low 5 · 12.2%Low 15 · 36.6%Moderate 1 · 2.4%High 0 · 0%

Unfractionated heparin vs low molecular weight heparin

Total VTE · people undergoing major amputation of the lower extremity

The review found no eligible studies for this question.

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Unfractionated heparin vs low molecular weight heparin

DVT (symptomatic, asymptomatic, non‐fatal) · people undergoing major amputation of the lower extremity

It is very uncertain whether unfractionated heparin changes DVT (symptomatic, asymptomatic, non‐fatal) (5 to 8 days after surgery) compared with low molecular weight heparin (very low certainty).

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity 2020 · Cochrane Headline outcomes only
OR 1.23 [0.28, 5.35]
1 study · 75 participants
Very low

Unfractionated heparin vs low molecular weight heparin

PE (symptomatic, asymptomatic, non‐fatal) · people undergoing major amputation of the lower extremity

The review found no eligible studies for this question.

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Unfractionated heparin vs low molecular weight heparin

All cause mortality · people undergoing major amputation of the lower extremity

The review found no eligible studies for this question.

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Unfractionated heparin vs low molecular weight heparin

Adverse events · people undergoing major amputation of the lower extremity

The review found no eligible studies for this question.

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Unfractionated heparin vs low molecular weight heparin

Bleeding (timing not specified) · people undergoing major amputation of the lower extremity

The review found no eligible studies for this question.

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Unfractionated heparin vs low molecular weight heparin

Successful prevention of clotting · CRRT

It is very uncertain whether unfractionated heparin changes successful prevention of clotting compared with low molecular weight heparin (very low certainty).

1 finding from 1 review

Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement… 2020 · Cochrane Headline outcomes only
RR 0.95 [0.7, 1.31]
1 study · 54 participants
Very low

Unfractionated heparin vs low molecular weight heparin

Treatment cessation due to adverse events · CRRT

Unfractionated heparin showed no clear difference in treatment cessation due to adverse events compared with low molecular weight heparin (low certainty).

1 finding from 1 review

Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement… 2020 · Cochrane Headline outcomes only
RR 0.29 [0.02, 3.53]
2 studies · 77 participants
Low

Unfractionated heparin vs low molecular weight heparin

Recovery of kidney function · CRRT

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Unfractionated heparin vs low molecular weight heparin

Thrombocytopenia · CRRT

It is very uncertain whether unfractionated heparin changes thrombocytopenia compared with low molecular weight heparin (very low certainty).

1 finding from 1 review

Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement… 2020 · Cochrane Headline outcomes only
RR 0.57 [0.2, 1.63]
2 studies · 124 participants
Very low

Unfractionated heparin vs low molecular weight heparin

Cost to health care services · CRRT

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Unfractionated heparin vs low molecular weight heparin

Major bleeding · CRRT

Unfractionated heparin showed no clear difference in major bleeding compared with low molecular weight heparin (low certainty).

1 finding from 1 review

Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement… 2020 · Cochrane Headline outcomes only
RR 0.58 [0.13, 2.58]
5 studies · 153 participants
Low

Unfractionated heparin vs low molecular weight heparin

Death: unknown time frame · CRRT

It is very uncertain whether unfractionated heparin changes death: unknown time frame compared with low molecular weight heparin (very low certainty).

1 finding from 1 review

Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement… 2020 · Cochrane Headline outcomes only
RR 0.78 [0.51, 1.18]
1 study · 29 participants
Very low

Subcutaneous unfractionated heparin vs unfractionated heparin

Symptomatic recurrent VTE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent VTE at 3 months compared with intravenous unfractionated heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism 2017 · Cochrane Headline outcomes only
OR 1.66 [0.89, 3.1]
8 studies · 965 participants
Low

Subcutaneous unfractionated heparin vs low molecular weight heparin

PE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in PE at 3 months compared with low molecular weight heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism 2017 · Cochrane Headline outcomes only
OR 0.84 [0.36, 1.96]
5 studies · 1819 participants
Low

Subcutaneous unfractionated heparin vs low molecular weight heparin

VTE‐related mortality4 · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in VTE‐related mortality at 3 months compared with low molecular weight heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism 2017 · Cochrane Headline outcomes only
OR 0.53 [0.17, 1.67]
8 studies · 2469 participants
Low

Subcutaneous unfractionated heparin vs low molecular weight heparin

Major bleedingd (3 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in major bleedingd (3 months) compared with low molecular weight heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism 2017 · Cochrane Headline outcomes only
OR 0.72 [0.43, 1.2]
5 studies · 2300 participants
Low

Subcutaneous unfractionated heparin vs low molecular weight heparin

All‐cause mortality (7 days ‐ 3 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in all‐cause mortality (7 days ‐ 3 months) compared with low molecular weight heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism 2017 · Cochrane Headline outcomes only
OR 0.73 [0.5, 1.07]
7 studies · 2272 participants
Low

Subcutaneous unfractionated heparin vs low molecular weight heparin

Asymptomatic VTE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

The review found no eligible studies for this question.

1 finding from 1 review

Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Subcutaneous unfractionated heparin vs unfractionated heparin

Symptomatic recurrent DVT at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent DVT at 3 months compared with intravenous unfractionated heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism 2017 · Cochrane Headline outcomes only
OR 3.29 [0.64, 17.06]
1 study · 115 participants
Low